For the quarter ending 2025-09-30, EVOK made $4,283,979 in revenue. -$1,156,208 in net income. Net profit margin of -26.99%.
| Income Statement | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-09-30 |
|---|---|---|---|---|
| Net product sales | 4,283,979 | 3,752,142 | 3,080,158 | 2,654,186 |
| Cost of goods sold | 101,977 | 167,679 | 41,613 | 104,024 |
| Research and development | 5,320 | 8,413 | 42,783 | 11,677 |
| Selling, general and administrative | 5,314,370 | 5,134,902 | 4,297,505 | 3,824,142 |
| Total operating expenses | 5,421,667 | 5,310,994 | 4,381,901 | 3,939,843 |
| Loss from operations | -1,137,688 | -1,558,852 | -1,301,743 | -1,285,657 |
| Interest income | 107,507 | 112,534 | 118,853 | 99,294 |
| Interest expense | 126,027 | 124,658 | 123,288 | 126,027 |
| Total other expense | -18,520 | -12,124 | -4,435 | -26,733 |
| Net loss | -1,156,208 | -1,570,976 | -1,306,178 | -1,312,390 |
| Earnings per share basic | -0.45 | -0.62 | -0.51 | -0.94 |
| Earnings per share diluted | -0.45 | -0.62 | -0.51 | -0.94 |
| Weighted average number of diluted shares outstanding | 2,557,408 | 2,553,174 | 2,548,684 | 1,399,882 |
| Weighted average number of shares outstanding basic | 2,557,408 | 2,553,174 | 2,548,684 | 1,399,882 |
Evoke Pharma Inc (EVOK)
Evoke Pharma Inc (EVOK)